STOCKS TELEGRAPH

Tag: ZOM

  • 2021 Revenue & Gross Margin Updates: Zomedica Corp. (ZOM) stock Rebounds After hours

    2021 Revenue & Gross Margin Updates: Zomedica Corp. (ZOM) stock Rebounds After hours

    On February 25, Zomedica Corp. (ZOM) provided its Q4 and fiscal 2021 revenue and gross margin update. Consequently, the stock rebounded in the after-hours on Friday.

    During the regular trading session, the stock suffered a loss of 3.32% at 37.86 million shares. ZOM closed the session at $0.35 per share after fluctuating between $0.34 and $0.38 during the session. Following the announcement, the stock made a comeback in the after-hours to gain a good 15.92%. Hence, ZOM was trading at a value of $0.40 per share at an after-hours volume of 14.48 million shares, on Friday.

    The veterinary health company, Zomedica Corp. was founded in 2013. Currently, its 979.89 million outstanding shares trade at a market capitalization of $342.18 million. ZOM stock has added a value of 13.93% year to date, while it subtracted a huge 81.33% last year.

    ZOM’s Revenue & Gross Margin

    For the fourth quarter and fiscal 2021, the company reported total revenue of $4.1 million, against $0 in the same periods of the previous year. Moreover, ZOM had a gross margin of 73.9% and cash and cash equivalents were $195 million at the end of 2021.

    In Q4, PluseVet’s revenue increased by 66% YOY to $4.0 million, against $2.4 million in the year-ago period.

    Furthermore, the TRUFORMA® product revenue increased by 22$ to $73,000 in Q4 2021, against $22,500 in the previous quarter.

    The company will release its complete Q4 and fiscal 2021 results on March 1, 2022. Additionally, the company’s progress and future outlook will be discussed during its Q1 Virtual Investor Summit on March 8, 2022.

    Management Team Additions

    Recently, the company announced multiple new additions to its management team, including:

    Firstly, on February 15, ZOM announced the appointment of Adrian Lock, Vice President, and General Manager, for leading its sales organization. Mr. Lock is the founding CEO of PluseVet and has been directing the company’s sales activities for over 10 years.

    Secondly, on February 07, with more than 25 years of experience, Nicole Westfall joined ZOM as the Vice President, Marketing.

    Thirdly, on January 25, with over 30 years of experience, Kristin Domanski was appointed as the Vice President, Human Resources of the company.

    And, on January 2, Tony Blair was appointed as the Executive Vice President, Operations, who comes with over 35 years of experience.

    In addition, Mr. Evan Saint-Peter has been promoted to the role of Vice President, Technology Innovation.

  • Zomedica Corp. (ZOM) Stock Gaining Momentum in Premarket. Here’s What’s Happening.

    Zomedica Corp. (ZOM) Stock Gaining Momentum in Premarket. Here’s What’s Happening.

    Zomedica Corp. (ZOM) is veterinary wellness and health-based company. It offers diagnostics and treatments for pets by fixing their unmet medical needs. The company’s product line includes novel diagnostics and devices, which are intended to improve the health of patients.

    The price of ZOM stock during the regular trading on February 17, 2022, was $0.40 with a gain of 5.26%. At last check in the premarket on February 18, 2022, the stock was further up by 7.17%.

    ZOM: Events and Happenings

    ZOM updated about its Executive management’s participation at the following events.

    • Midwest Veterinary Conference held on February 17-19, 2022.
    • Music City Veterinary Conference being held on February 18-20, 2022, and
    • Q4 Earnings Release Conference is being held on February 25, 2022.

    On February 15, 2022, ZOM updated that the Company’s sales organization is now led by Adrian Lock. He was Vice President and General Manager of the company and will lead sales management and professional service veterinarians. On January 27, 2022, ZOM provided an update on its business and marketing activities in Q1 2022. On December 15, 2021, ZOM announced its Executive management’s presence at the Virtual H.C. Wainwright BioConnect 2022 Conference held on 10-13, 2022.

    ZOM: Key Financials

    On November 12, 2021, ZOM released its financial results for the third fiscal quarter 2021 ended September 30, 2021. Some of the key updates are mentioned below.

    Revenue

    Net revenue in Q3 2021 was $22.5 thousand compared to no revenue in the same quarter of 2020. The company reported an increase in its revenue over the year.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $6.34 million or $0.01 against $4.97 million or $0.01 in the same quarter of 2020. The net loss of the company increased over the yearly period.

    On October 01, 2021, ZOM was informed about the acquisition of Pulse Veterinary Technologies for $70.9 million. Pulsevet is a leading electro-hydraulic shock wave technology for the treatment of a wide range of veterinary patients.

    Conclusion

    ZOM stock down-performed by 81% in the past year as the economic turmoil surrounded the international businesses due to pandemics. The current stock market gain by the company is likely the result of its announcement related to attendance of veterinary conferences and earnings release calls.

  • Zomedica Corp. (ZOM) soared in the current session; here’s why

    Zomedica Corp. (ZOM) soared in the current session; here’s why

    In the current market, Zomedica Corp. (ZOM) stock plummeted by 0.77% to the price of $0.84 at the time of writing. ZOM stock closed its previous trading session at $0.85.

    The expansion of a direct sales team and organization for ZOM and TRUFORMA

    The ZOM stock announced on 15th April 2021 that it has planned to expand its operations of commercialization, marketing and sales of its product. Zomedica will do so by expanding the direct sales organization and at the same time shifting from its distributor-based sales effort.

    The ZOM stock wants to transition into the distributor-based sales model as quickly as possible because the anticipated disruption and changes in the current distributor has limited the ability for the company to market its products effectively. Therefore accelerating towards the direct sales organization is the immediate operative goal and transition that the company is working on.

    Initially affect the sales of TRUFORMA and other products but only for the short term; in the long term the operative process of direct sales will strengthen the development, commercialization, and sales of any future product along with TRUFORMA.

    The accelerated process of developing the direct sales team has proven effective because the company has a current sales force of eight employees as direct field sales personnel that come under two regional managers and the executive vice president of sales and chief commercial officer.

    The company believes that this direct sales force will dramatically improve the ability to serve the customers and effectively sell the products in the veterinary market based on the long-term plan. For this, the first commercial sale of the company’s product before its launch date has been a sign of high expectations of demand for TRUFORMA and Zomedica’s financial strength.

    The potential of ZOM stock’s performance and sales of TRUFORMA in 2021

    With the latest milestone in its flagship product, we need to look into the stats of the pet diagnostic market. The most significant data about the market is that 93% of the dog owners visit veterinary annually and with the average lifespan of dogs in mind, that means they will visit for 15 years give or take. Furthermore, 67% of the households keep a single pet at least and $99 billion is the amount that consumers spent on their pets in the US, 2020.

    The performance of the sales operation gives and potential market share gives investors and shareholders a positive expectation for the ZOM stock. However, there is still the volatility of the stock in the past one-year trend that needs to be heeded.

    These stats are very welcoming for Truforma and with other assays in the phase to be released soon, 2021 seems highly for ZOM stock to rise. Zomedica has also submitted an in the company’s SEC 10-K form, a bull thesis which indicates the market potential for companion animal diagnostic market forecasted to reach $2.8 billion  (a 5-year CAGR of 9.8%) by 2024. Similarly, the global veterinary immunodiagnostic market has been forecasted to reach $2.1 billion by 2022 (CAGR 9.6%) This potential is well within reach as the company keeps reaching its milestones one by one.

  • Zomedica Corp. (ZOM) stock plunged in the pre-market trading session: here’s why

    Zomedica Corp. (ZOM) stock plunged in the pre-market trading session: here’s why

    Zomedica Corp (ZOM) stock recently traded at $1.33 which is an 8.90% downward movement. The ZOM stock previously closed at $1.46. ZOM stock also plunged in the pre-market trading session by 11.28% at the time of writing.

    The recent pattern of negative movement in the ZOM stock isn’t due to any recent PR news as of April. But this stock has been known to be volatile and gives traders quick short gains or losses if they are not lucky.

    About Zomedica Corp

    Zomedica Corp (NYSE: ZOM) is a veterinary health company that creates commercial products for pets specifically cats and dogs. They focus especially on delivering and innovating products which tend to be the unmet needs of the clinical veterinarians.

    Dwelling deeper into the ZOM stock performance

    Zomedica Corp (ZOM) stock due to its volatility pattern in 2021 would suggest that it should not be kept for the long position. In the month of December 2020, the stock was worth 20-25 cents per share however it entered the year 2021 with a bounce in price up to $1.30 and didn’t stop there. It shot well over the $2 mark and up to $2.91 in February. However, the stock has jumped down from the peak-price climb and now is around $1.30-$1.35 per share.

    If you have experience with trading in for short positions and swift market timing then this stock can definitely give you a reward. For that it is also important that you understand what is the recent operational activities happening in the ZOM stock’s fundamentals;

    Zomedica has released a veterinary diagnosis-kit that has been tailor made and sold known as TRUFORMA. This was delivered on 16th March, ahead of the announced 30th March date. It is an on-site canine eACTH assay that is created for the purpose of eliminating the risk of sample transport error. Furthermore, it aids in the diagnosis of adrenal disease. To learn more, read our article covering this news by clicking here.

    What makes ZOM stock so special?

    With the latest milestone in its flagship product, we need to look into the stats of the pet diagnostic market. The most significant data about the market is that 93% of the dog owners visit veterinary annually and with the average lifespan of dog in mind, that means they will visit for 15 years give or take. Furthermore, 67% of the households keep a single pet at least and $99 billion is the amount that consumers spent on their pets in the US, 2020.

    These stats are very welcoming for Truforma and with other assays in the phase to be released soon, 2021 seems highly for ZOM stock to rise. Zomedica has also submitted an in the company’s SEC 10-K form, a bull thesis which indicates the market potential for companion animal diagnostic market forecasted to reach $2.8 billion  (a 5-year CAGR of 9.8%) by 2024. Similarly, the global veterinary immunodiagnostic market has been forecasted to reach $2.1 billion by 2022 (CAGR 9.6%) This potential is well within reach as the company keeps reaching its milestones one by one.

  • The Three Cheap Stocks to Keep in your Investment List

    The Three Cheap Stocks to Keep in your Investment List

    The global pandemic has affected many high price stocks and with much uncertainty, we have certain cheap stocks to watch for.

    Last year has been total devastation and things have turned upside down for most of the companies in the stock market. We have seen many companies whose dynamics have changed during the last years’ time. For instance, companies which totally relied upon retail store have understood the significance of online stores and are moving to e-market—now.

    In the meantime, the investor’s behavior changed due to rising uncertainty and for risk-averse investors, the cheap stocks with high potential are the best investment options. Let’s see the three cheap stocks for investment.

    Zomedica (ZOM)

    Zomedica (ZOM) is one of the most promising cheap stocks in the market. Zomedica is a development stage veterinary diagnostic and pharmaceutical company for dogs and cats. The company is well-positioned and has improved its performance during 2020 following a rise in pets’ products.

    Recently, Zomedica recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization. This will help the company grow its sales and give a competitive edge in the market. It’s a long-term success story for the company and investors would be quite proud of it.

    Zomedica (ZOM) is trading on a lower side, which could be a perfect buy for investors. The future outlook seems solid. So, ZOM wouldn’t be a bad investment at all.

    Navient (NAVI)

    Navient (NAVI) provides loans to students. The company menacing time in 2020 as the borrowers disappear in quarantine. Reporting one of its worst ever, Navient saw 28.5% of its federal loan borrowers and 14.7% of its private loan borrowers hiding themselves during Q2. However, things improved with the following figures dropping to 13.8% and 3.9% on federal and private loans, respectively.

    Navient stock is trading around its new 52-week high price of $14 as the bullish sentiment continues to increase. The rising bulls are largely pushed by the anticipation of increasing recovery of the finance sector. Moreover, the company expects to see higher charge-offs during the year, jumping from 0.88% in 2020 to 3% in 2021. Overall, Navient is quite optimistic about its fortune this year, which will bring improvements in lending.

    Glu Mobile (GLUU)

    Glu Mobile (GLUU) has been performing radiantly, recently. The company was mostly driven by the announcement of EA following the all-cash buyout deal with Glu at an implied enterprise value of $2.1 billion.EA has high expectations from Glu’s rising sales and positive operating profits right away. The acquisition is expected to close in Q2 2021, based on the shareholder’s consent.

    In the fourth quarter, the company reported impressive outcomes with revenue jumping up to 25% year over year to $141.4 million. The GAAP net income rose to a record $23.9 million quarterly. While the free cash flow was also great with 46.2 million by the end of the quarter and $69.0 million by the year-end, up 132%. The prospects are strong for Glu Mobile (GLUU) as the acquisition is forthcoming.

  • Zomedica Corp.’s (ZOM) stock soars due to positive announcement

    Zomedica Corp.’s (ZOM) stock soars due to positive announcement

    Zomedica Corp.’s (NYSE: ZOM) stock has soared by 8.73% to the current value of $2.49.  In the after-hours market, the ZOM stock rose by %10.84.

    One of the major news that comes adjacent to the positive movement in the ZOM stock is its ability to sell its first commercial unit of the unique and valuable diagnostic tool kit. This tool kit was delivered to the veterinary market slightly ahead of the announced schedule.

    About Zomedica Corp

    ZomedicaCorp (NYSE American: ZOM) is a veterinary health company that creates commercial products for pets, specifically cats and dogs. They focus primarily on delivering and innovating products that tend to be the clinical veterinarians’ unmet needs. Market and business-wise, this is a brilliant tactic in which the Corp. stays ahead of the competition with its differentiated products that have more probability of being recommended by the clinical veterinarians.

    TRUFORMA delivered before its announced sale date

    The kit that has been tailor-made and sold is known as TRUFORMA, which was delivered ahead of the announced 30th March date. What this instrument does is that it is an on-site canine eACTHessay that is created to eliminate the risk of sample transport error. Furthermore, it aids in the diagnosis of adrenal disease.

    TRUFORMA was made true thanks to the collaboration of the employees at ZOM and a team of scientists/researchers at the Qorvo Biotechnologies LLC that worked as a development partner. Qorvo Biotechnologies, with the help of their special Bulk Acoustic Wave (BAW) radio frequency (RF) technology, can disrupt the veterinarian market with this innovative milestone in the form of veterinarian diagnostic.

    TRUFORMA sold to an established veterinary hospital

    The first official purchaser of the veterinarian diagnostic system-TRUFORMA is Jason Berg, DVM (Doctor of Veterinary Medicine), DACVIM (Diplomate, American College of Veterinary Internal Medicine). This is again a very clever marketing tactic because Jason Berg is the president and founder of Guardian Veterinary Specialists, an emergency critical care hospital located in New York. Dr. Berg is recognized professionally for his work as a veterinary internist and neurologist. Furthermore, Dr. Berg is a lecturer and a researcher who published several articles and professional journals that American Veterinary Medical Association has reviewed.

    What makes TRUFORMA so unique?

    Apart from this eACTH cortisol assay, there are two more out of the five initial assays available for commercial selling ahead of their time. T4 and endogenous ACTH are expected to be available soon while TSH, cortisol, and total T4 being commercially ready.

    This news is good for the ZOM stock’s positive movement because, in the field of clinical veterinary, vets have to depend on serum cortisol measurements to cater to adrenal diseases in dogs. With TRUFORMA’s enhanced efficacy and accuracy in cortisol assay, what is essentially going to revolutionize is how veterinarians will treat life-threatening adrenal diseases and give comforting news to the owners of the pets.

  • Early Morning Vibes: Check Out These 4 hot Stocks Right Now

    Early Morning Vibes: Check Out These 4 hot Stocks Right Now

    Stock markets recovered strongly from the price dip at the end of January last week. In New York, the indices even managed to set new all-time highs on the boards. On Friday, the S&P 500 closed 0.39% higher at 3,886 points and the Nasdaq celebrated the weekend with a gain of 0.57% on 13,856 points.

    The unemployment figures on Friday showed that the labor market is slowly but surely going to recover somewhat. In January, 49,000 jobs were added in the private sector and the unemployment rate fell to 6.3%. Wall Street had previously expected more jobs, but economists assumed an unchanged unemployment rate at 6.7%. Still, the numbers were not very positive. Unemployment fell mainly because 406,000 people gave up their job search. The participation rate thus fell to 61.4%. This is a bad sign and indicates that the US job market is in bad shape.

    To support the US economy, Joe Biden is currently preparing a $ 1,900 billion corona support package. The package includes $ 1,400 in incentive vouchers, supplemental unemployment benefits, and Covid-19 vaccination and testing funds. Treasury Secretary Janet Yellen said on Sunday that if Biden’s stimulus plan is passed, the US could return to full employment by 2022.

    The S&P 500 nevertheless managed to close in the green for five days in a row and appears to continue this series today. Futures are up approximately 0.4% and there is little on the agenda to change that. Figures from Twitter, Uber, Walt Disney, and Coca-Cola will follow later this week. Furthermore, inflation figures from the US, China, and Germany are on the agenda.

    Today Top Movers

    Aurora Mobile Ltd (JG) grew over 25.50% at $6.25 in pre-market trading ‎today after declaring a partnership agreement with iQIYI (IQ)‎, to develop a smart advertising and marketing ecosystem. ‎

    Ocugen, Inc (OCGN) stock moved up 68.76 percent to $8.86 in the pre-market ‎trading.‎ The company recently declared a $23 million registered direct offering of common stock priced at a premium to market. ‎

    Westport Fuel Systems Inc (WPRT) gained over 49.13% at $12.90 in pre-market ‎trading on Monday.‎ ‎

    Sundial Growers Inc (SNDL) is up more than 0.88% at $1.14 in pre-market ‎hours ‎Monday ‎February 08, 2021.‎

    Top Upgrades & Downgrades

    RBC Capital turned bullish on The Hershey Company (HSY), upgrading the stock to “Outperform” and assigning a $170.0 price target, representing a potential upside of 15.95% from Friday’s close. 

    The Estee Lauder Companies Inc. (EL) has won the favor of Jefferies’s equity research team. The firm upgraded the shares from Hold to Buy and moved their price target to $310.0, suggesting a 13.59% additional upside for the stock. 

    CorEnergy Infrastructure Trust Inc. (CORR) received an upgrade from analysts at DA Davidson, who also set their one-year price target on the stock to $9.5. They changed their rating on CORR to Neutral from Underperform in a recently issued research note. 

    Earlier Monday Raymond James reduced its rating on Iridium Communications Inc. (IRDM) stock to Market Perform from Outperform. 

    UBS analysts reduced their investment ratings, saying in research reports covered by the media that its rating for ViacomCBS Inc. (VIAC) has been changed to Sell from Neutral. 

    Analysts at BofA downgraded Las Vegas Sands Corp. (LVS)’s stock to Neutral from Buy Monday.

    Latest Insider Activity

    Zomedica Corp. (ZOM) Director MACLEOD CHRISTOPHER ROSS announced the sale of shares taking place on Feb 03 at $1.10 for some 6,400 shares. The total came to more than $7047.

    Zynga Inc. (ZNGA) Director DUGAN REGINA E sold on Feb 04 a total 217,319 shares at $10.27 on average. The insider’s sale generated proceeds of almost $91917.

    Harley-Davidson Inc. (HOG) President and CEO ZEITZ JOCHEN declared the purchase of shares taking place on Feb 04 at $32.47 for some 30,800 shares. The transaction amount was around $1.0 million.

    Amicus Therapeutics Inc. (FOLD) Director WHITMAN BURKE W bought on Feb 01 a total 41,467 shares at $19.09 on average. The purchase cost the insider an estimated $28,637.

  • 23 Stocks Making Sharp Moves in Pre Market Session

    23 Stocks Making Sharp Moves in Pre Market Session

    ‎Bionano Genomics Inc. (BNGO) stock soared 46.62% to $1.95 in the pre-‎market ‎trading after reporting that Praxis Genomics, LLC received accreditation from the College of ‎American ‎Pathologists (CAP). The most recent rating by Ladenburg Thalmann, on September 24, 2020, ‎is a Buy.‎

    ‎Tenax Therapeutics Inc. (NASDAQ: TENX) shares are trading down -7.07% at $1.84 ‎at ‎the time of writing. Company’s 52-week ranged between $0.25 to $2.68.‎

    ‎Ideanomics Inc. (IDEX) stock soared 2.87% to $2.15 in the pre-market trading. ‎The ‎company recently revealed that its Mobile Energy Global (“MEG”) and its contracting entity ‎Qingdao ‎Chengyang Medici have signed an agreement with Meihao Chuxing, a joint venture between ‎BYD and ‎Didi, to purchase an initial 2,000 units of model BYD D1. ‎

    ‎Oxbridge Re Holdings Limited (OXBR) stock moved down -6.83 percent to $1.91 ‎in ‎the pre-market trading.‎

    ‎Guardion Health Sciences Inc. (NASDAQ: GHSI) shares are trading up 12.48% ‎at ‎‎$0.4289 at the time of writing. The firm lately declared the appointment of seasoned ‎nutritional ‎products industry leader Bret Scholtes as President and Chief Executive Officer. Company’s ‎‎52-week ‎ranged between $0.17 to $0.74.‎

    ‎Gevo Inc. (GEVO) is down more than -4.76% at $4.4 in pre-market ‎hours ‎Wednesday December 30, 2020. The stock had dropped over -4.15% to $4.62 in the last ‎trading ‎session.‎

    ‎Universal Security Instruments Inc. (UUU) stock moved up 5.0 percent to $5.25 ‎in ‎the pre-market trading following its statement regarding recent market activity in the ‎Company’s ‎stock.‎

    ‎Marathon Patent Group Inc. (MARA) gained over 10.03% at $12.94 in pre-‎market ‎trading Wednesday December 30, 2020. The company recently reported that it has entered ‎into a ‎contract with Bitmain to purchase 70,000 Antminer S-19 ASIC miners.‎

    Before the trading started on December 30, 2020, Ocugen Inc. (OCGN) is down -‎‎‎7.83% to reach $2.0. It has been trading in a 52-week range of $0.17 to $3.05.‎

    Before the trading started on December 30, 2020, Moderna Inc. (MRNA) is ‎up ‎‎3.59% to reach $118.5 following the declaration from the company that the it is engaged in ‎discussions ‎with the government of South Korea to potentially provide 40 million or more doses of the ‎Moderna ‎COVID-19 Vaccine to support South Korea’s aim of providing vaccines to the public as soon as ‎possible. ‎It has been trading in a 52-week range of $17.68 to $178.50.‎

    ‎Riot Blockchain Inc. (RIOT) stock soared 6.02% to $16.74 in the pre-market trading.‎

    ‎Technical Communications Corporation (NASDAQ: TCCO) shares are trading down -‎‎‎16.78% at $4.76 at the time of writing after declaring its results for the fiscal year ended September ‎‎26, ‎‎2020. Company’s 52-week ranged between $1.72 to $7.00.‎

    ‎Tonix Pharmaceuticals Holding Corp. (TNXP) is up more than 2.21% at $0.6695 ‎in ‎pre-market hours Wednesday December 30, 2020. The stock had dropped over -6.16% to $0.65 in ‎the ‎last trading session.‎

    ‎AstraZeneca PLC (AZN) gained over 2.26% at $51.03 in pre-market ‎trading ‎Wednesday December 30, 2020 after receiving approval of its coronavirus vaccine in U.K.‎

    ‎New Concept Energy Inc. (AMEX: GBR) shares are trading down -14.75% at $2.08 ‎at ‎the time of writing. Company’s 52-week ranged between $0.55 to $2.19.‎

    ‎Moleculin Biotech Inc. (MBRX) stock plunged -1.67% to $0.8279 in the pre-‎market ‎trading after declaring that that the US Food and Drug Administration (FDA) has granted ‎Orphan Drug ‎Designation (ODD) to Annamycin for treatment of soft tissue sarcomas.‎

    ‎MoSys Inc. (MOSY), a Semiconductors company, dropped about -13.22% at $2.1 ‎in ‎pre-market trading Wednesday.‎

    Before the trading started on December 30, 2020, Greenpro Capital Corp. (GRNQ) ‎is ‎down -2.15% to reach $1.82. The company lately revealed that it intends to set up a Bitcoin ‎‎($BTC) ‎Fund for investment. It has been trading in a 52-week range of $0.21 to $3.12.‎

    ‎Nxt-ID Inc. (NXTD) gained over 9.92% at $1.44 in pre-market trading ‎Wednesday ‎December 30, 2020.‎

    ‎Hepion Pharmaceuticals Inc. (HEPA) gained over 50.0% at $3.12 in pre-‎market ‎trading Wednesday December 30, 2020 after declaring positive top line data for low dose ‎CRV431 in ‎Phase 2a ‘AMBITION’ clinical trial for treatment of Advanced NASH.‎

    ‎XPeng Inc. (XPEV) is up more than 3.13% at $42.85 in pre-market hours ‎Wednesday ‎December 30, 2020. The stock had jumped over 9.31% to $41.55 in the last trading session.‎

    ‎BioNTech SE (BNTX) is up more than 3.5% at $91.37 in pre-market hours ‎Wednesday ‎December 30, 2020 following declaration from the financial magazine Caixin that Shanghai ‎Fosun ‎Pharmaceutical Group will set up a joint venture with BioNTech to produce COVID-19 vaccines in ‎China. ‎The stock had jumped over 0.19% to $88.28 in the last trading session.‎

    Before the trading started on December 30, 2020, Bit Digital Inc. (BTBT) is up ‎‎14.58% ‎to reach $12.1. It has been trading in a 52-week range of $0.28 to $12.45.‎

  • Market Movers: What changed for these 21 stocks while you were sleeping

    Market Movers: What changed for these 21 stocks while you were sleeping

    ‎Greenpro Capital Corp. (GRNQ), a Conglomerates company, dropped about -‎‎5.88% ‎at $1.76 in pre-market trading Tuesday after announcing Bitcoin fund.‎

    ‎ATIF Holdings Limited (ATIF) stock plunged -8.51% to $0.9698 in the pre-‎market ‎trading.‎

    ‎Bionano Genomics Inc. (BNGO) stock soared 8.57% to $0.96 in the pre-‎market ‎trading after declaring that Praxis Genomics, LLC received accreditation from the College of ‎American ‎Pathologists (CAP). The most recent rating by Ladenburg Thalmann, on September 24, 2020, ‎is a Buy. ‎

    ‎Zomedica Corp. (AMEX: ZOM) shares are trading up 4.5% at $0.2625 at the ‎time ‎of ‎writing. Company’s 52-week ranged between $0.06 to $0.50.‎

    ‎Nano Dimension Ltd. (NASDAQ: NNDM) shares are trading up 5.52% at $8.6 at ‎the ‎time of writing after pricing $250 million registered direct offering. ‎Company’s 52-week ‎ranged ‎between $0.51 to $10.49. Analysts have a consensus price target of $8. ‎

    ‎Jaguar Health Inc. (JAGX) stock moved down -2.88 percent to $0.7325 in the pre-‎‎market trading.‎

    ‎Ideanomics Inc. (IDEX), a Software – Application company, rose about 4.27% at ‎‎$2.44 ‎in pre-market trading Tuesday following the declaration the signing of an agreement of its ‎Mobile ‎Energy Global (“MEG”) and contracting entity Qingdao Chengyang Medici with Meihao ‎Chuxing, a joint ‎venture between BYD and Didi, to purchase an initial 2,000 units of model BYD D1. ‎

    ‎Alibaba Group Holding Limited (BABA) is up more than 3.64% at $230.45 in pre-‎‎‎market hours Tuesday December 29, 2020. The stock had jumped over 0.16% to $222.36 in ‎the ‎last ‎trading session.‎

    Before the trading started on December 29, 2020, FuelCell Energy Inc. (FCEL) is ‎up ‎‎2.3% to reach $11.81. It has been trading in a 52-week range of $0.84 to $13.91.‎

    ‎AeroCentury Corp. (ACY) lost over -25.7% at $10.29 in pre-market trading ‎Tuesday ‎December 29, 2020 following the update of listing standards compliance.‎

    ‎Color Star Technology Co. Ltd. (CSCW) is down more than -9.21% at $0.69 in pre-‎‎‎market hours Tuesday December 29, 2020. The stock had jumped over 7.04% to $0.76 in ‎the ‎last ‎trading session.‎

    Before the trading started on December 29, 2020, Guardion Health Sciences ‎Inc. ‎‎(GHSI) is up 14.83% to reach $0.36. The firm recently reported the appointment of ‎Bret ‎Scholtes, as its President and Chief Executive Officer, and as a member of the Board of Directors. ‎He is ‎a veteran of the nutritional products industry for nearly a decade. It has been trading in a 52-‎week ‎range of $0.17 to $0.74.‎

    ‎Nokia Corporation (NOK) stock soared 2.31% to $3.99 in the pre-market ‎trading ‎after reporting that it has been selected by Thailand’s dtac as its first 5G partner.‎ The most ‎recent ‎rating by Exane BNP Paribas, on October 30, 2020, is a Neutral. ‎

    Before the trading started on December 29, 2020, Acasti Pharma Inc. (ACST) is ‎up ‎‎7.32% to reach $0.3343. It has been trading in a 52-week range of $0.17 to $2.75.‎

    ‎RMG Acquisition Corp. (RMG) grew over 2.1% at $32.61 in pre-market trading ‎today ‎following the stockholder approval of business combination with Romeo Systems, Inc. with ‎no ‎redemptions.‎

    ‎Aprea Therapeutics Inc. (APRE), a Biotechnology company, rose about 4.73% ‎at ‎‎$5.76 in pre-market trading Tuesday after declaring results of primary endpoint from Phase 3 trial ‎of ‎Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS).‎

    ‎MicroVision Inc. (NASDAQ: MVIS) shares are trading up 6.41% at $7.14 at ‎the ‎time ‎of writing. Company’s 52-week ranged between $0.15 to $9.74. Analysts have a consensus ‎price ‎target ‎of $4.50.‎

    ‎China Recycling Energy Corporation (CREG) is down more than -2.23% at $5.7 in pre-‎‎market hours Tuesday December 29, 2020 after revealing that it has entered into agreement to ‎acquire ‎Xi’an Taiying Energy Saving Technology ‎Co., Ltd..‎. The stock had jumped over 31.31% to $5.83 in ‎the last ‎trading session. ‎

    ‎BIOLASE Inc. (BIOL) stock moved up 25.44 percent to $0.6021 in the pre-‎market ‎trading.‎

    ‎Borr Drilling Limited (BORR), a Oil & Gas Drilling company, rose about 4.66% ‎at ‎‎$0.854 in pre-market trading Tuesday after reporting the appointment of Mr. Magnus Vaaler as its ‎new ‎Chief Financial Officer. He will replace Mr. Christoph Bausch.‎

    ‎Onconova Therapeutics Inc. (NASDAQ: ONTX) shares are trading up 3.68% ‎at ‎‎$0.465 ‎at the time of writing. Company’s 52-week ranged between $0.19 to $1.56. Analysts have ‎a ‎consensus ‎price target of $7.50.‎

  • Pre-Market Cues: 24 Stocks Roaring for Change On December 28th

    Pre-Market Cues: 24 Stocks Roaring for Change On December 28th

    ‎Avinger Inc. (AVGR) stock plunged -7.38% to $0.4445 in the pre-market trading. The ‎most recent rating by Ladenburg Thalmann, on March 09, 2018, is a Buy. The company lately ‎announced annual meeting results.‎

    ‎Jaguar Health Inc. (JAGX) is up more than 16.5% at $0.833 in pre-market ‎hours ‎Monday December 28, 2020 after signing second agreement for $6 million non-dilutive ‎financing ‎transaction involving the sale of royalty rights. The stock had dropped over -33.18% to $0.71 ‎in the last ‎trading session.‎

    ‎Ocugen Inc. (NASDAQ: OCGN) shares are trading up 52.84% at $2.69 at the time of ‎writing. Company’s 52-week ranged between $0.17 to $3.05.‎

    ‎Senseonics Holdings Inc. (SENS) tumbled over -13.63% at $0.786 in pre-market ‎trading today after declaring financial and operational business updates.‎

    ‎Naked Brand Group Limited (NAKD), a Apparel Manufacturing company, rose about ‎‎2.63% at $0.2145 in pre-market trading Monday after reporting that it has been granted an additional ‎‎180-day period, or until May 24, 2021.‎

    ‎Zomedica Corp. (ZOM) gained over 13.05% at $0.259 in pre-market trading Monday ‎December 28, 2020.‎

    Before the trading started on December 28, 2020, Sundial Growers Inc. (SNDL) is up ‎‎9.23% to reach $0.517. The company today declared concentrates license agreement with Simply ‎Solventless. It has been trading in a 52-week range of $0.14 to $3.88.‎

    ‎Acasti Pharma Inc. (ACST) stock soared 14.17% to $0.377 in the pre-market trading. ‎The most recent rating by Oppenheimer, on September 01, 2020, is a Perform.‎

    ‎Camber Energy Inc. (AMEX: CEI) shares are trading down -7.62% at $0.97 at the time ‎of writing. Company’s 52-week ranged between $0.46 to $4.10.‎

    ‎NIO Limited (NIO), a Auto Manufacturers company, rose about 1.92% at $46.65 in ‎pre-market trading Monday.‎

    ‎FuelCell Energy Inc. (FCEL) stock moved up 10.0 percent to $13.53 in the pre-market ‎trading.‎

    ‎Tonix Pharmaceuticals Holding Corp. (TNXP) gained over 7.86% at $0.7173 in pre-‎market trading Monday December 28, 2020. The firm recently revealed that it has completed the ‎purchase of an approximately 44-acre site in Hamilton, Montana, for the construction of a vaccine ‎development and commercial scale manufacturing facility. ‎

    ‎Guardion Health Sciences Inc. (GHSI) is down more than -9.47% at $0.3097 in pre-‎market hours Monday December 28, 2020. The stock had dropped over -7.89% to $0.34 in the last ‎trading session.‎

    Before the trading started on December 28, 2020, Color Star Technology Co. Ltd. ‎‎(CSCW) is up 30.76% to reach $0.9284. It has been trading in a 52-week range of $0.31 to ‎‎$2.06.‎

    ‎Ampio Pharmaceuticals Inc. (AMPE) stock soared 8.49% to $2.3 in the pre-market ‎trading. The most recent rating by ROTH Capital, on December 19, 2019, is a Buy.‎

    ‎Blink Charging Co. (BLNK), a Specialty Retail company, rose about 4.24% at $51.6 in ‎pre-market trading Monday.‎

    ‎Nikola Corporation (NKLA) stock moved up 2.18 percent to $14.05 in the pre-market ‎trading.‎

    ‎Onconova Therapeutics Inc. (ONTX) gained over 3.39% at $0.4905 in pre-market ‎trading Monday December 28, 2020.‎

    Before the trading started on December 28, 2020, MicroVision Inc. (MVIS) is up ‎‎4.43% to reach $6.84. It has been trading in a 52-week range of $0.15 to $9.74.‎

    ‎Nano Dimension Ltd. (NNDM) stock plunged -13.51% to $7.62 in the pre-market ‎trading after pricing $250 million registered direct offering. The most recent rating by Maxim Group, on ‎October 21, 2016, is a Buy.‎

    ‎Plug Power Inc. (NASDAQ: PLUG) shares are trading up 5.37% at $37.49 at the time ‎of writing. Company’s 52-week ranged between $2.53 to $37.11. Analysts have a consensus price ‎target of $24.‎

    ‎Marathon Patent Group Inc. (MARA) grew over 31.23% at $14.33 in pre-market ‎trading today.‎

    ‎Riot Blockchain Inc. (RIOT), a Software – Application company, rose about 18.22% at ‎‎$15.51 in pre-market trading Monday.‎

    ‎Marathon Oil Corporation (MRO) stock moved up 3.32 percent to $6.85 in the pre-‎market trading.‎